In the IMpower133 study, the combination of atezolizumab, an inhibitor of PD-L1, with etoposide and carboplatin significantly improved OS and progression-free survival (PFS) in patients with ES-SCLC compared to placebo with etoposide and carboplatin (9). This evidence concerns the gene CD274 and small cell lung carcinoma.